肺炎支原体肺炎患儿血清白细胞介素-6及可溶性白细胞介素-6受体活性变化及意义

目的：为正确认识肺炎支原体肺炎(MPP)患儿免疫状态，该研究检测了MPP和非肺炎支原体肺炎患儿血清白细胞介素6(IL6)及可溶性白细胞介素6受体(sIL6R)的变化，探讨其对MPP和非MPP患儿病情的影响，并为选择合理的MPP治疗手段提供理论依据。方法：用ELISA法检测MPP患儿(n=41)及非MPP患儿(n=20)急性期和恢复期血清IL-6及sIL-6R含量。结果：①MPP 患儿血清IL-6急性期和恢复期分别为 2.01±0.41，1.12±0.67 ng/L；sIL-6R急性期和恢复期分别为 1.87±0.25，1.92±0.27 μg/L，均明显高于正常对照组 0.37±0.52 ng/L，1.71±0.15 μg/L，差异有显著性(P<0.01)；MPP患儿恢复期血清IL-6含量较急性期明显下降，差异有显著性(P<0.01)，而sIL-6R恢复期与急性期比较差异无显著性(P>0.05)；②非MPP患儿血清IL-6急性期及恢复期分别为1.56±0.26，0.84±0.63 ng/L，明显高于正常对照组，差异有显著性(P<0.01或P<0.05)，而血清sIL-6R与对照组比较差异无显著性(P>0.05)；非MPP患儿急性期血清IL-6高于恢复期，差异有显著性(P<0.05)，血清sIL-6R急性期与恢复期比较差异无显著性(P>0.05)；③MPP患儿急性期血清IL-6、sIL-6R含量较非MPP患儿急性期升高(P<0.01或P<0.05)；MPP患儿恢复期血清IL-6含量与非MPP患儿恢复期的差异无显著性(P>0.05)；MPP患儿恢复期血清sIL-6R含量明显高于非MPP患儿恢复期(P<0.01)。结论：MPP患儿血清IL-6及sIL-6R改变较非MPP患儿明显，提示MPP患儿免疫功能改变较非MPP患儿显著，IL-6及sIL-6R参与了MPP的发生和发展，有必要对MPP患儿进行免疫调节治疗。

Serum levels of interleukin-6 and soluble interleukin-6 receptor in children with Mycoplasma pneumoniae pneumonia

Objective This study aims to investigate the immune state of children with Mycoplasma pneumoniae pneumonia (MPP) so as to provide evidence for determining the treatment regime of MPP. Methods Enzyme linked immunoassay was used to measure serum interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R) levels in children with either MPP (MPP group, n=41) or bronchopneumonia with negative MP-IgM (non-MPP group, n=20). Twenty healthy children served as the Normal control group. Results Serum levels of IL-6 and sIL-6R in the MPP group were significantly higher than those of the Normal control group in both the acute and recovery stages (P< 0.01). Serum IL-6 levels of the non-MPP group in the acute and recovery stages were significantly higher than those of the Normal control group (P< 0.01, P< 0.05, respectively), while serum sIL-6R level was not different between them. In the recovery stage,serum IL-6 levels in both the MPP and non-MPP groups reduced significantly compared with those of the acute stage (P <0.01), while serum sIL-6R levels remained at a high level. The children in the MPP group had higher levels of serum IL-6 and sIL-6R in the acute stage than those of the non-MPP group (P< 0.05). In the recovery stage, the serum sIL-6R levels of the MPP group were still significantly higher than those of the non-MPP group (P< 0.01), while the difference of serum IL-6 between the two groups was not significant. Conclusions There may be more remarkable immune function disorders in children with MPP compared to children with non-MPP. Immune regulation therapy seems to be necessary for children with MPP.